[HTML][HTML] Thyroid carcinoma: epidemiology, histology, and diagnosis

JP Shah - Clinical advances in hematology & oncology: H&O, 2015 - ncbi.nlm.nih.gov
The incidence of thyroid cancer has risen in recent years. In the United States, the incidence
increased at an annual rate of 5.4% in men and 6.5% in women from 2006 to 2010. 1 …

[HTML][HTML] BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients

L Jin, E Chen, S Dong, Y Cai, X Zhang, Y Zhou… - Oncotarget, 2016 - ncbi.nlm.nih.gov
The role of telomerase reverse transcriptase (TERT) gene promoter mutations in the
aggressiveness of papillary thyroid cancer (PTC) remains to be further investigated. Here we …

[引用][C] The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives

K Kakudo, A Bychkov, Y Bai, Y Li, Z Liu… - Pathology …, 2018 - Wiley Online Library
The new World Health Organization (WHO) classification of endocrine organs was
published in 2017 and several amendments were made to the classification of thyroid …

The BRAFV600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single …

R Elisei, D Viola, L Torregrossa… - The Journal of …, 2012 - academic.oup.com
Background: The BRAF V600E mutation, the most frequent genetic alteration in papillary
thyroid carcinoma (PTC), was demonstrated to be a poor prognostic factor. The aim of this …

The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading

CC Juhlin, O Mete, ZW Baloch - Endocrine-related cancer, 2023 - erc.bioscientifica.com
The 5th edition of the Classification of Endocrine and Neuroendocrine Tumors has been
released by the World Health Organization (WHO). This timely publication integrates several …

The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta‐analysis

TH Kim, YJ Park, JA Lim, HY Ahn, EK Lee, YJ Lee… - Cancer, 2012 - Wiley Online Library
BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …